Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Tranexamic acid (TXA) and ε-aminocaproic acid (EACA) are two drugs shown to limit blood loss
following major surgery, from cardiac to orthopedic procedures. Yet compared to tranexamic
acid (TXA), research on the clinical impact of ε-aminocaproic acid (EACA) in total knee
arthroplasty (TKA) is limited. The primary aim of this study is to determine whether TXA and
EACA provide similar blood decreasing effects following TKA or whether one drug provides a
superior effect over the other in reducing patients' blood loss.
Phase:
Phase 4
Details
Lead Sponsor:
Miller Orthopedic Specialists
Collaborators:
CHI Health Mercy Hospital Creighton University Medical Center